Title Lead Abstract Presentation Session Room/
Author # date/time Details
(CDT)
Avelumab
Avelumab (MSB0010718C; M Patel 777PD October 9 Poster Athens
anti-PD-L1) in patients 16:30-17:30 Discussion
with metastatic Session
urothelial carcinoma Genitourinary
progressed after tumors, non-
platinum-based therapy prostate
or platinum ineligible
Phase 1b dose-finding Poster Athens
study of avelumab J Larkin 775PD October 9 Discussion
(anti-PD-L1) + axitinib 16:30-17:30 Session
in treatment-naïve Genitourinary
patients with advanced tumors, non-
renal cell carcinoma prostate
Evaluation of real J Becker 1154P October 9 Poster Display Hall E
world treatment 13:00-14:00 Session
outcomes in patients
with metastatic Merkel
cell carcinoma (MCC)
following second line
chemotherapy
A multicenter, T Powles 842TiP October 9 Poster Display Hall E
international, 13:00-14:00 Session
randomized, open-label
phase 3 trial of
avelumab + best
supportive care (BSC)
vs BSC alone as
maintenance therapy
after first-line
platinum-based
chemotherapy in
patients with advanced
urothelial cancer
(JAVELIN Bladder 100)
Phase 3 study of R Motzer 844TiP October 9 Poster Display Hall E
avelumab in combination 13:00-14:00 Session
with axitinib versus
sunitinib as first-line
treatment for patients
with advanced renal
cell carcinoma (aRCC)
Title Lead Abstract Presentation Session Room/
Author # date/time Details
(CDT)
Tepotinib
Tepotinib plus Y-L Wu 1257P October 8 Poster Display Hall E
gefitinib in patients 13:00-14:00 Session
with
c-Met-positive/EGFR-mut
ant NSCLC: recommended
phase II dose (RP2D),
tolerability, and
efficacy
Design of a phase II Y-L Wu 1287TiP October 8 Poster Display Hall E
trial comparing 13:00-14:00 Session
tepotinib + gefitinib
with cisplatin +
pemetrexed in EGFR
inhibitor-resistant,
c-Met+ NSCLC
A phase II trial P Paik 1292TiP October 8 Poster Display Hall E
investigating the 13:00-14:00 Session
highly selective c-Met
inhibitor tepotinib in
stage IIIB/IV lung
adenocarcinoma with MET
exon 14 alterations
after failure of at
least one prior therapy
For further information and press materials please visit:http://www.emdgroup.com/emd/media/media_...
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Avelumab
Avelumab (also known as MSB0010718C) is an investigational, fully human antibody specific for a protein found on tumor cells called PD-L1, or programmed death ligand-1. Avelumab is thought to have a dual mechanism of action which may enable the immune system to find and attack cancer cells. By binding to PD-L1, avelumab is thought to prevent tumor cells from using PD-L1 for protection against white blood cells such as T-cells, exposing them to anti-tumor responses. Avelumab is also thought to help white blood cells such as natural killer (NK) cells find and attack tumors in a process known as ADCC, or antibody-dependent cell-mediated cytotoxicity. In November 2014, Merck KGaA, Darmstadt, Germany, and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.
About Erbitux
Erbitux(R) is a highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). As a monoclonal antibody, the mode of action of Erbitux is distinct from standard non-selective chemotherapy treatments in that it specifically targets and binds to the EGFR. This binding inhibits the activation of the receptor and the subsequent signal-transduction pathway, which results in reducing both the invasion of normal tissues by tumor cells and the spread of tumors to new sites. It is also believed to inhibit the ability of tumor cells to repair the damage caused by chemotherapy and radiotherapy and to inhibit the formation of new blood vessels inside tumors, which appears to lead to an overall suppression of tumor growth.
The most commonly reported side effect with Erbitux is an acne-like skin rash. In approximately 5% of patients, hypersensitivity reactions may occur during treatment with Erbitux; about half of these reactions are severe.
Erbitux has already obtained market authorization in over 90 countries world-wide for the treatment of colorectal cancer and for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Merck KGaA, Darmstadt, Germany, licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. Merck KGaA, Darmstadt, Germany, has an ongoing commitment to the advancement of oncology treatment and is currently investigating novel therapies in highly targeted areas.
About Tepotinib
Tepotinib (also known as MSC2156119J) is an investigational small-molecule inhibitor of the c-Met receptor tyrosine kinase capable of inhibiting both hepatocyte growth factor-dependent and -independent c-MET activation in low nanomolar concentrations. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib is currently under evaluation in Phase I/II trials.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of EUR 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck KGaA, Darmstadt, Germany, name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
(Logo: http://photos.prnewswire.com/prnh/201606... )
Contact: Heike Schmiedt +49-6151-72-7498
Photo:
http://photos.prnewswire.com/prnh/201606...
